The skeletal effects of the tyrosine kinase inhibitor nilotinib

Bone

Volumn 49, Issue 2, 2011, Pages 281-289

  O'Sullivan, Susannah ^a   Lin, Jian Ming ^a   Watson, Maureen ^a   Callon, Karen ^a   Tong, Pak Cheung ^a   Naot, Dorit ^a   Horne, Anne ^a   Aati, Opetaia ^a   Porteous, Fran ^a   Gamble, Greg ^a   Cornish, Jillian ^a   Browett, Peter ^a   Grey, Andrew ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Mitogenesis; Nilotinib; Osteoblasts; Osteoclasts; Osteoprotegerin; Platelet derived growth factor

Indexed keywords

ABELSON KINASE; IMATINIB; NILOTINIB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY MASS; BONE DENSITY; BONE MARROW CELL; BONE METABOLISM; BONE TURNOVER; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOGENETICS; DISEASE DURATION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; FEMALE; GENE SILENCING; HUMAN; MALAISE; MALE; MITOGENESIS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PANCYTOPENIA; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION;

ADULT; ANIMALS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOGENESIS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RATS; RNA INTERFERENCE;

EID: 79958770455     PISSN: 87563282     EISSN: 87563282     Source Type: Journal    
DOI: 10.1016/j.bone.2011.04.014     Document Type: Article

References (39)

1. Weisberg E., Manley P., Mestan J., Cowan-Jacob S., Ray A., Griffin J.D. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006, 94:1765-1769.
2. Verstovsek S., Akin C., Manshouri T., Quintas-Cardama A., Huynh L., Manley P., et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 2006, 30:1365-1370.
3. Weisberg E., Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Ray A., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
4. Manley P.W., Cowan-Jacob S.W., Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005, 1754:3-13.
5. Brownlow N., Russell A.E., Saravanapavan H., Wiesmann M., Murray J.M., Manley P.W., et al. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia 2008, 22:649-652.
6. Taylor J.R., Brownlow N., Domin J., Dibb N.J. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 2006, 25:147-151.
7. Manley P.W., Drueckes P., Fendrich G., Furet P., Liebetanz J., Martiny-Baron G., et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010, 1804:445-453.
8. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
9. Ray A., Cowan-Jacob S.W., Manley P.W., Mestan J., Griffin J.D. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007, 109:5011-5015.
10. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
11. Montemurro M., Schoffski P., Reichardt P., Gelderblom H., Schutte J., Hartmann J.T., et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009, 45:2293-2297.
12. von Bubnoff N., Gorantla S.P., Thone S., Peschel C., Duyster J. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006, 107:4970-4971.
13. von Bubnoff N., Gorantla S.H., Kancha R.K., Lordick F., Peschel C., Duyster J. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 2005, 19:1670-1671.
14. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
15. Kantarjian H.M., Giles F.J., Bhalla K.N., Pinilla-Ibarz J., Larson R.A., Gattermann N., et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011, 117:1141-1145.
16. Berman E., Nicolaides M., Maki R.G., Fleisher M., Chanel S., Scheu K., et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006, 354:2006-2013.
17. Dewar A.L., Doherty K.V., Hughes T.P., Lyons A.B. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol 2005, 83:48-56.
18. Dewar A.L., Domaschenz R.M., Doherty K.V., Hughes T.P., Lyons A.B. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 2003, 17:1713-1721.
19. Dewar A.L., Farrugia A.N., Condina M.R., Bik To L., Hughes T.P., Vernon-Roberts B., et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 2006, 107:4334-4337.
20. El Hajj Dib I., Gallet M., Mentaverri R., Sevenet N., Brazier M., Kamel S. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 2006, 551:27-33.
21. Grey A., O'Sullivan S., Reid I.R., Browett P. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 2006, 355:2494-2495.
22. Jonsson S., Olsson B., Ohlsson C., Lorentzon M., Mellstrom D., Wadenvik H. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008, 93:1101-1103.
23. O'Sullivan S., Horne A., Wattie D., Porteous F., Callon K., Gamble G., et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009, 94:1131-1136.
24. O'Sullivan S., Naot D., Callon K., Porteous F., Horne A., Wattie D., et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007, 22:1679-1689.
25. Owen S., Hatfield A., Letvak L. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006, 355:627.
26. Fitter S., Dewar A.L., Kostakis P., To L.B., Hughes T.P., Roberts M.M., et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008, 111:2538-2547.
27. Fierro F., Illmer T., Jing D., Schleyer E., Ehninger G., Boxberger S., et al. Inhibition of platelet-derived growth factor receptor? by imatinib mesylate suppresses proliferation and alters differentiation of human mesencymal stem cells in vitro. Cell Prolif 2007, 40:355-366.
28. Tibullo D., Giallongo C., La Cava P., Berretta S., Stagno F., Chiarenza A., et al. Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol 2009, 37:461-468.
29. Gallet M., Mentaverri R., Sevenet N., Brazier M., Kamel S. Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor. Apoptosis 2006, 11:1909-1921.
30. Grey A., Banovic T., Naot D., Hill B., Callon K., Reid I., et al. Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases. Endocrinology 2001, 142:1098-1106.
31. Groot C.G., Danes J.K., van der Meer J.M., Herrmann-Erlee M.P. Osteocalcin antigenicity in cultured osteoblast-like cells after stimulation with 1,25-vitamin D3. Cell Biol Int Rep 1985, 9:528.
32. The effect of PTH and PGE2 on growth and differentiation of primary fetal rat osteblast-like cells, on UMR 106 osteosarcoma cells, and on a SV40 transformed "osteoblast-like" cell line. Int Conf IX on Calcium Regulating Hormones and Bone Metabolism 1986, M.P.M. Herrmann-Erlee, J.M. van der Meer (Eds.).
33. Cornish J., Callon K.E., Lin C.Q., Xiao C.L., Mulvey T.B., Coy D.H., et al. Dissociation of the effects of amylin on osteoblast proliferation and bone resorption. Am J Physiol 1998, 274:E827-E833.
34. Grey A., Chen Q., Xu X., Callon K., Cornish J. Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology 2003, 144:4886-4893.
35. Middleton-Hardie C., Zhu Q., Cundy H., Lin J.M., Callon K., Tong P.C., et al. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. J Bone Miner Res 2006, 21:438-445.
36. Walton R.J., Bijvoet O.L. A simple slide-rule method for the assessment of renal tubular reaborption of phosphate in man. Clin Chim Acta 1977, 81:273-276.
37. Grey A., Bolland M., Gamble G., Wattie D., Horne A., Davidson J., et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007, 92:1305-1310.
38. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boyle W.J., Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15:2-12.
39. Li B., Boast S., de los Santos K., Schieren I., Quiroz M., Teitelbaum S.L., et al. Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat Genet 2000, 24:304-308.